Literature DB >> 29138154

Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.

Alex Mu1, Erica Weinberg2, Dwight E Moulin3, Hance Clarke4.   

Abstract

OBJECTIVE: To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain. QUALITY OF EVIDENCE: A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement. MAIN MESSAGE: Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.
CONCLUSION: Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29138154      PMCID： PMC5685445     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


  74 in total

1.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

2.  Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin.

Authors:  Nicola Torrance; Blair H Smith; Margaret C Watson; Michael I Bennett
Journal:  Fam Pract       Date:  2007-08-01       Impact factor: 2.267

3.  Development and testing of a neuropathic pain screening questionnaire: ID Pain.

Authors:  Russell Portenoy
Journal:  Curr Med Res Opin       Date:  2006-08       Impact factor: 2.580

Review 4.  A review of the use of methadone for the treatment of chronic noncancer pain.

Authors:  Mary E Lynch
Journal:  Pain Res Manag       Date:  2005       Impact factor: 3.037

5.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).

Authors:  Didier Bouhassira; Nadine Attal; Haiel Alchaar; François Boureau; Bruno Brochet; Jean Bruxelle; Gérard Cunin; Jacques Fermanian; Patrick Ginies; Aurélie Grun-Overdyking; Hélène Jafari-Schluep; Michel Lantéri-Minet; Bernard Laurent; Gérard Mick; Alain Serrie; Dominique Valade; Eric Vicaut
Journal:  Pain       Date:  2005-01-26       Impact factor: 6.961

6.  Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.

Authors:  S H Sindrup; F W Bach; C Madsen; L F Gram; T S Jensen
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

7.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Authors:  M B Max; S A Lynch; J Muir; S E Shoaf; B Smoller; R Dubner
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

Review 8.  Review article: perioperative pain management of patients on methadone therapy.

Authors:  Philip W H Peng; Paul S Tumber; Douglas Gourlay
Journal:  Can J Anaesth       Date:  2005-05       Impact factor: 5.063

9.  The prescription of medical cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: a case report.

Authors:  Howard Meng; John G Hanlon; Rita Katznelson; Anand Ghanekar; Ian McGilvray; Hance Clarke
Journal:  Can J Anaesth       Date:  2015-10-27       Impact factor: 5.063

10.  Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy.

Authors:  Rob Allen; Uma Sharma; Suna Barlas
Journal:  J Pain Res       Date:  2014-06-23       Impact factor: 3.133
View more
  20 in total

1.  [Cannabinoids in pain medicine].

Authors:  M Karst
Journal:  Schmerz       Date:  2018-10       Impact factor: 1.107

2.  Nortriptyline safer than amitriptyline?

Authors:  Cait O'Sullivan; Cristi Froyman
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

3.  Composition of Canadian Pain Society guideline development group?

Authors:  Joel R Lexchin
Journal:  Can Fam Physician       Date:  2018-01       Impact factor: 3.275

Review 4.  [Diagnostics and therapy of neuropathic pain].

Authors:  G Gossrau; R Sabatowski
Journal:  Anaesthesist       Date:  2021-10-21       Impact factor: 1.041

5.  Mindfulness-Based Stress Reduction in Breast Cancer Survivors with Chronic Neuropathic Pain: A Randomized Controlled Trial.

Authors:  Yaadwinder Shergill; Danielle B Rice; Eve-Ling Khoo; Virginia Jarvis; Tinghua Zhang; Monica Taljaard; Keith G Wilson; Heather Romanow; Brittany Glynn; Rebecca Small; Joshua A Rash; Andra Smith; Lynette Monteiro; Catherine Smyth; Patricia A Poulin
Journal:  Pain Res Manag       Date:  2022-07-07       Impact factor: 2.667

6.  A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.

Authors:  Sebastian Jugl; Aimalohi Okpeku; Brianna Costales; Earl J Morris; Golnoosh Alipour-Haris; Juan M Hincapie-Castillo; Nichole E Stetten; Ruba Sajdeya; Shailina Keshwani; Verlin Joseph; Yahan Zhang; Yun Shen; Lauren Adkins; Almut G Winterstein; Amie Goodin
Journal:  Med Cannabis Cannabinoids       Date:  2021-02-25

7.  A Comprehensive Algorithm for Management of Neuropathic Pain.

Authors:  Daniel Bates; B Carsten Schultheis; Michael C Hanes; Suneil M Jolly; Krishnan V Chakravarthy; Timothy R Deer; Robert M Levy; Corey W Hunter
Journal:  Pain Med       Date:  2019-06-01       Impact factor: 3.750

Review 8.  Tapentadol for neuropathic pain: a review of clinical studies.

Authors:  Ulderico Freo; Patrizia Romualdi; Hans G Kress
Journal:  J Pain Res       Date:  2019-05-16       Impact factor: 3.133

9.  Ultralow-Dose Adjunctive Methadone with Slow Titration, Considering Long Half-Life, for Outpatients with Cancer-Related Pain.

Authors:  Srini Chary; Amane Abdul-Razzak; Lyle Galloway
Journal:  Palliat Med Rep       Date:  2020-07-10

10.  Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.

Authors:  Esraa Aly; Willias Masocha
Journal:  IBRO Neurosci Rep       Date:  2021-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.